Relay Therapeutics Q3 net loss $84.2M ($0.76/sh); RLY-4008 88% ORR in FGFR2-fusion CCA

Relay Therapeutics, Inc.

2022-Q3 EPS reported -$2.04 revenue$1,128,000

Net loss $84.2M vs $60.8M YoY; R&D expenses rose to $66.9M from $45.0M.
Cash and investments $1.1B as of Sep 30, 2022; sufficient to fund operations into 2025.
RLY-4008 interim data: 88% ORR at pivotal dose in FGFRi-naive FGFR2-fusion cholangiocarcinoma (n=17).
Raised $300M gross proceeds in follow-on public offering during Q3.
RLY-2608 (PI3Kα inhibitor) continues enrolling in single-agent and combination cohorts.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Relay Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income Net loss was $84.2 million for the third quarter of 2022, or a net loss per share of $0.76, EPS $0.76.

Period: the quarter ended September 30, 2022
Net income: Net loss was $84.2 million for the third quarter of 2022, or a net loss per share of $0.76
EPS: $0.76
Result: reported results

Exact text from the filing

Relay Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2022.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Relay Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-021868

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.